Search Tag: #ESCcongress
Top Cardiology Stories of 2019
2019 27 Dec
As we move into 2020, here's a quick recap of our most clicked stories in Cardiology in 2019: ORION-10 Trial: Inclisiran Effective at Reducing LDL Findings from the ORION-10 trial presented at the AHA Scientific Session in 2019 showed that twice-yearly injections of inclisiran were effective at reducing LDL cholesterol. ENCOURAGE... Read more
New Management Pathways in Cardiovascular Risk Factors
2019 02 Oct
Summary: A presentation of a case study in light of the updated ESC guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. Several new guidelines were released at the European Society of Cardiology (ESC) Congress in Paris, France. These included updated guidelines on lipid control and new guidelines... Read more
#ESCCongress: Artificial Intelligence for Heart Attack Prediction
2019 04 Sep
New findings presented at the ESC Congress in Paris demonstrated technology that uses artificial intelligence (AI) to identify people at high risk of a fatal heart attack at least five years before it strikes. These findings are published in the European Heart Journal. The technology has been developed by researchers at the University of Oxford.... Read more
#ESCCongress: New Management Pathways in Cardiovascular Risk Factors
2019 03 Sep
At the ESC Congress this year, several new guidelines have been released including updated guidelines on lipid control and new guidelines on diabetes and cardiovascular disease. As per the updated guidelines on lipid control , the following are some key recommendations: Low-density lipoprotein (LDL) cholesterol levels should be lowered... Read more
#ESCCongress: DAPA-HF Trial - Reduction in Cardiovascular Death, Hospitalisation
2019 01 Sep
The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris. DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,... Read more
#ESCCongress: THEMIS/THEMIS-PCI Findings - Minimal Benefits Observed
2019 01 Sep
Investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) study at the ESC Congress in Paris. The THEMIS trial evaluated whether adding ticagrelor to aspirin improved... Read more
#ESCCongress: PARAGON-HF Trial Misses Endpoint
2019 01 Sep
Findings from the PARAGON-HF trial were presented in the first hot-line session at the ESC Congress today in Paris. Investigators from Brigham and Women's Hospital presented the results of the Prospective Comparison of ARNI with ARB Global Outcome in HF With Preserved Ejection Fraction (PARAGON-HF). This is the largest, randomised clinical trial... Read more
#ESCCongress: How Has Social Media Changed Clinical Cardiology Practice
2019 31 Aug
In a very interesting session at the #ESCCongress in Paris on the use of #SoMe in cardiology, Prof. Mamas A. Mamas of the University of Keele talked about ways in which social media can and has changed clinical practice in cardiology. Practice in medicine is led by randomised control trials. All these trials eventually inform clinical guidelines.... Read more
#ESCCongress: Text Messages Help Patients with Diabetes - CHAT-DM Study
2019 31 Aug
New findings from the CHAT-DM study presented at the ESC Congress today report that text message intervention can result in better glycaemic control in patients with diabetes mellitus and coronary heart disease. Findings were just published in Circulation: Cardiovascular Quality and Outcomes. According to the study author Dr. Xiqian Huo of... Read more
#ESCCongress: Findings from the EVOPACS Study
2019 31 Aug
Despite the fact that guidelines recommend the initiation of high-intensity statin therapy in patients with acute coronary syndrome (ACS), target levels are not achieved in a large number of patients. Evolocumab, a rapidly acting, low-density lipoprotein cholesterol (LDL-C) Lowering drug had so far not been studied in the acute phase of acute coronary... Read more